Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS) today and set a price target of $36. The company’s shares opened today at $21.78, close to its 52-week low of $19.85.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 6.1% and a 41.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, representing a 30.4% upside. In a report issued on July 25, J.P. Morgan also maintained a Buy rating on the stock with a $34 price target.
See today’s analyst top recommended stocks >>
Based on Alkermes’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $41.99 million. In comparison, last year the company had a GAAP net loss of $32.65 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
